- 1、本文档共35页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
* Then in 2010, Rosenberg published encouraging results from so-called chimeric antigen receptor therapy, or CAR therapy—a personalized treatment that involves genetically modifying a patient’s T cells to make them target tumor cells. One group, led by Carl June at the University of Pennsylvania, began reporting eye-catching responses to CAR therapy: patients with pounds of leukemia that melted away. At a meeting in New Orleans this month, June’s team and another at Memorial Sloan-Kettering Cancer Center in New York reported that the T cell therapy in their studies put 45 of 75 adults and children with leukemia into complete remission, * The apparent increases in tumor burden that sometimes precede responses in patients receiving immune therapy may reflect either continued tumor growth until a sufficient immune response develops or transient immune-cell infiltrate with or without edema. These analyses show that 9.7% (22 of 227) of treated patients, who were initially characterized as PD by WHO criteria, have evidence of activity consistent with a response to ipilimumab. * * * 解读IRC评价标准在实体瘤中的应用 Breakthrough of the year 2013 Why? Antibodies against CTLA-4 Antibodies against PD-1 Chimeric antigen receptor therapy, or CAR therapy CAR therapy Adoptive cell transfer therapy with CAR-engineered T cells Result Immunity and Cancer: immunoediting PD-L1 in Cancer Expressed on cell surface of ~30% solid tumors and selected hematologic malignancies; Inhibits anti-tumor immune responses. PD-1 pathway immunotherapy 20~50% response rate in clinical trials PD-1 pathway antagonists show broad anti-tumor activity response in: melanoma, RCC, NSCLC, gastric, head and neck, ovarian, colon malignancies. Patterns of response to ipilimumab observed in advanced melanoma Clin Cancer Res 2009;15:7412-7420. PD? Resected metastatic melanoma tumor nodule of the lung SD may also be viewed as an indicator of meaningful therapeutic effect LATE BREAKING ABSTRACT: Pooled analysis of long-ter
文档评论(0)